Aggressive lymphoma - CAR-T & transplant
LINKS TO ABSTRACTS:
Presentation ID p423-1
Presenter: Caroline Besson, Le Chesnay, France
The study authors conclude that patients with B-cell non-Hodgkin lymphoma hospitalized for Covid-19 have a high incidence of prolonged evolution of SARS-CoV-2 infection. Administration of anti-CD20 therapy within the last 12 months is one of the main risk factors for longer in-hospital stay and death of Covid-19. The study shows that the risk of persistent Covid-19 was also higher in patients older than 70 years or with refractory or relapsed disease. These findings may contribute to guiding the management of lymphoma patients during the Covid-19 pandemic.
Presentation ID p423-2
Presenter: Steven Le Gouill, France
The study authors conclude that this first analysis from DESCAR-T registry seems to confirm CAR-T cells efficacy in real life and be in line with previously published data. Updated results are presented at the meeting.
Presentation ID p423-3
Presenter: Hui Shi, China
The study authors conclude that their findings confirm the existence of molecular subtypes of R&R DLBCL, providing evidence that the curative effect of CAR T cells immunotherapy differs in diverse subtypes. CAR T cells immunotherapy can prolong survival times in some subtypes thought previously associated with worse outcomes. We provide potential precision-medicine strategies for R&R DLBCL patients with poor prognoses.
Presentation ID p423-4
Presenter: Shigeru Kusumoto, Nagoya, Japan
The study authors conclude that these results demonstrate that valemetostat has an acceptable safety profile in patients with R/R NHLs and encouraging efficacy results in patients with R/R PTCL or R/R ATL and warrants further evaluation.
Presentation ID p423-5
Presenter: Gerald Illerhaus, Germany
The study authors conclude that the MATRIX regimen was associated with excellent long-lasting survival in PCNSL patients ≤70 ys. WBRT and ASCT exhibit similar efficacy. They further conclude that in comparison with the other therapeutic arms, MATRIX and ASCT were not associated with higher non-relapse mortality and incidence of second tumors, whereas impairment of specific cognitive functions after WBRT was confirmed.